

ALLERGAN INC  
Form 8-K  
May 21, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**May 21, 2014**

**Date of Report (Date of Earliest Event Reported)**

**ALLERGAN, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

<b>Delaware</b>	<b>1-10269</b>	<b>95-1622442</b>
<b>(State of Incorporation)</b>	<b>(Commission File Number)</b>	<b>(IRS Employer</b>
	<b>2525 Dupont Drive</b>	<b>Identification Number)</b>
	<b>Irvine, California 92612</b>	
<b>(Address of Principal Executive Offices) (Zip Code)</b>		

Edgar Filing: ALLERGAN INC - Form 8-K

**(714) 246-4500**

**(Registrant's Telephone Number, Including Area Code)**

N/A

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On May 21, 2014, Mr. Michael R. Gallagher, lead independent director of the Board of Directors of Allergan, Inc., sent a letter to Pershing Square Capital Management, L.P. A copy of the letter is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Letter dated May 21, 2014 from Mr. Gallagher to Pershing Square Capital Management, L.P.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALLERGAN, INC.**

Date: May 21, 2014

By: /s/ Matthew J. Maletta

Name: Matthew J. Maletta

Title: Vice President,

Associate General Counsel and Secretary

**Exhibit Index**

<b>Exhibit</b>	<b>Description of Exhibit</b>
99.1	Letter dated May 21, 2014 from Mr. Gallagher to Pershing Square Capital Management, L.P.